Co-Deletion of Chromosome 1p/19q and IDH1/2 Mutation in Glioma Subsets of Brain Tumors in Chinese Patients by Ren, Xiaohui et al.
Co-Deletion of Chromosome 1p/19q and IDH1/2
Mutation in Glioma Subsets of Brain Tumors in Chinese
Patients
Xiaohui Ren
1, Xiangli Cui
1, Song Lin
1*, Junmei Wang
2, Zhongli Jiang
1, Dali Sui
1,J i n gL i
1,
Zhongcheng Wang
2
1Neurosurgery, Capital Medical University, Beijing Tiantan Hospital, Beijing, China, 2Beijing Neurosurgical Institute, Beijing, China
Abstract
Objective: To characterize co-deletion of chromosome 1p/19q and IDH1/2 mutation in Chinese brain tumor patients and to
assess their associations with clinical features.
Methods: In a series of 528 patients with gliomas, pathological and radiological materials were reviewed. Pathological
constituents of tumor subsets, incidences of 1p/19q co-deletion and IDH1/2 mutation in gliomas by regions and sides in the
brain were analyzed.
Results: Overall, 1p and 19q was detected in 339 patients by FISH method while the sequence of IDH1/2 was determined in
280 patients. Gliomas of frontal, temporal and insular origin had significantly different pathological constituents of tumor
subsets (P,0.001). Gliomas of frontal origin had significantly higher incidence of 1p/19q co-deletion (50.4%) and IDH1/2
mutation (73.5%) than those of non-frontal origin (27.0% and 48.5%, respectively) (P,0.001), while gliomas of temporal
origin had significantly lower incidence of 1p/19q co-deletion (23.9%) and IDH1/2 mutation (41.7%) than those of non-
temporal origin (39.9% and 63.2%, respectively) (P=0.013 and P=0.003, respectively). Subgroup analysis confirmed these
findings in oligoastrocytic and oligodendroglial tumors, respectively. Although the difference of 1p/19q co-deletion was not
statistically significant in temporal oligodendroglial tumors, the trend was marginally significant (P=0.082). However,
gliomas from different sides of the brain did not show significant different pathological constituents, incidences of 1p/19q
co-deletion or IDH1/2 mutation.
Conclusion: Preferential distribution of pathological subsets, 1p/19q co-deletion and IDH1/2 mutation were confirmed in
some brain regions in Chinese glioma patients, implying their distinctive tumor genesis and predictive value for prognosis.
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Introduction
Glioma is the most common primary intracranial tumor [1].
According to 2007 WHO Classification of Tumors of the Central
Nervous System [2], gliomas consist of all brain tumors that are of
glial cell origin, accounting for almost 80% of primary malignant
brain tumors [3]. They are graded according to biological
behavior of the tumors. With the exception of pilocytic
astrocytomas, the prognosis of glioma patients is still poor, though
combined modality therapy and individualized treatment have
been widely used [1].
Co-deletion of chromosome 1p/19q, as a recognized prognostic
predictor, is associated with a good prognosis and increased
responsiveness to chemotherapy. High incidence of 1p and 19q
deletion is observed in oligodendroglioma and oligoastrocytoma
[4]. Co-deletion of 1p and 19q is associated with longer
progression-free time and longer median survival time, thus
representing an independent prognostic factor in anaplastic
oligodendroglial tumors (WHO grade III) [5,6,7,8]. Similarly,
1p/19q co-deletion also predicts a longer radiographic response to
temozolomide and is associated with both superior overall survival
and progression-free survival in low-grade oligodendroglial tumors
[9,10,11,12].
The discovery of somatic mutations in the isocitrate dehydro-
genase (IDH) enzymes through a genome-wide mutational analysis
in glioblastoma represents a milestone event in cancer biology
[13]. Recent reports showed IDH1 mutations in astrocytic and
oligodendroglial tumors (WHO grade II and III) and in secondary
glioblastomas with a frequency of up to 90%, whereas IDH1
mutations occurred in only 5% of primary glioblastomas [14].
Patients with diffusely infiltrative gliomas carrying an IDH1
mutation have a significantly longer overall survival compared to
patients with IDH1 wild type [15,16]. IDH1 codon 132 mutations
were found to be associated with reduced NADP-dependent IDH
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glioblastoma to irradiation and chemotherapy, thus explaining the
prolonged survival of patients with mutated glioblastoma [17].
Recently, several studies implied that gliomas located at
different part of the brain might harbor individualized patholog-
ical constituents. Larjavaara et al. demonstrated considerable
heterogeneity in the anatomic distribution of gliomas within the
brain [18]. Duffau et al. reported that low-grade gliomas were
located preferentially in the ‘‘secondary’’ functional areas,
especially within the region of the supplementary motor area
and the insular lobe [19]. Besides, some studies identified an
association between the incidence of 1p/19q co-deletion, IDH1/2
mutation and tumor locations. Zlatescu et al. suggested that tumor
genotypes were closely associated with tumor locations [20],
because they found that anaplastic oligodendrogliomas located in
the frontal, parietal, and occipital lobes were significantly more
likely to harbor allelic loss of chromosome 1p and 19q than
histologically indistinguishable tumors arising in the temporal lobe,
insula, and diencephalon; in addition, loss of heterozygosity (LOH)
for 1p and 19q was significantly associated with a bilateral pattern
of growth. Mueller et al. reported that allelic loss of 1p and 19q
was significantly less frequent in temporal oligodendrogliomas and
oligoastrocytomas [21]. Huang et al. reported that oligodendrog-
lial tumors having LOH of 1p and 19q occurred most frequently
in the non-temporal lobes [22]. Goze et al. reported a relatively
lower incidence of allelic loss of chromosome 1p and 19q in a
consecutive series of 12 Grade II gliomas involving the insula [23].
However, Wu et al. reported a high rate of 1p/19q co-deletion in
insular oligodendroglial tumors [24]. It was also found that IDH1
mutant glioblastomas predominantly involved the frontal lobe
[25].
To investigate whether subsets, 1p/19q co-deletion and IDH1/
2 mutation of the tumors are correlated with tumor locations in
Chinese glioma patients, we analyzed a series of 528 gliomas for
the correlation of their pathological constituents of subsets, the
incidence of 1p/19q co-deletion and IDH1/2 mutation with
tumor locations.
Materials and Methods
Ethics statement
All patients provided written informed consent for the current
study and the clinical study was approved by the Medical Ethics
Committee of Capital Medical University.
Patients and tissue samples
A series of 528 primary glioma patients, including 308 male and
220 female, were surgically treated in the Department of
Supratentorial Neoplasms of Beijing Tiantan Hospital between
January 2008 and September 2010. The patients’ ages ranged
from 14 to 68 years old with a mean of 41.5611.6 years. This
series of 528 gliomas consisted of 108 astrocytoma WHO grade II
(A), 45 anaplastic astrocytoma WHO grade III (AA), 88 primary
glioblastoma WHO grade IV (G), 80 oligodendroglioma WHO
grade II (O), 37 anaplastic oligodendroglioma WHO grade III
(AO), 99 oligoastrocytoma WHO grade II (OA) and 71 anaplastic
oligoastrocytoma WHO grade III (AOA). All glioma cases
enrolled in the Department of Neuropathology, Beijing Neuro-
surgical Institute, were examined and graded independently by
two neuropathologists who were blind to tumor genotypes,
according to the 2007 World Health Organization (WHO)
Classification of Tumors of the Central Nervous System [2].
Histological diagnoses of tumor specimens were reviewed and
confirmed by a third neuropathologist. If the first two pathologists
did not agree on the diagnosis, a third senior neuropathologist
would make the judge. If the three neuropathologists could not
make agreement, this case would be submitted to the pathological
committee of Beijing Neurosurgical Institute and Beijing Tiantan
Hospital for final diagnosis. The committee was composed of 10
senior neuropathologists and final diagnosis would be made only
when more than 6 of them agreed on it.
Detection of deletion of 1p/19q by the fluorescence in
situ hybridization (FISH) method
FISH was used for the detection of 1p/19q deletion in a series of
339 gliomas as a routine test from Jan 2009, including 150
astrocytic, 111 oligoastrocytic, and 78 oligodendroglial tumors.
The 1p/19q fluorescent probe kit (Vysis, USA) was used for the
FISH test. Breifly, 4 mm thick paraffin slides were deparaffinized,
dehydrated, and incubated in 1 mol/L NaSCN for 35 min at
80uC. Slides were then immersed in pepsin solution (0.65% in
protease buffer with 0.01 mol/L HCl) for 10 min at 37uC, and
tissues were fixed by 10% neutral buffered formalin. Then the
specimens were dehydrated in ethanol (70%, 85%, and 100%,
2 min in each bath) and air-dried, 20 ul of each probe was then
added separately, and slides were sealed with rubber cement. After
co-denaturation for 10 min at 75uC, the slides were then put in a
humidified atmosphere with Hybrite (ThermoBrite
TM vysis) 16 h
at 37uC. Slides were immersed first in 26SSC/0.3% NP-40 for
2 min at RT and then in 26SSC/0.3% NP-40 for 2 min at 73uC.
After drying, nuclei were counterstained with 4, 6-diamidino- 2-
phenylindole (DAPI) and antifade compound (Pphenylenedia-
mine). FISH signals for each locus-specific FISH probe were
assessed under an Olympus BX51TRF microscope (Olympus,
Ina-shi, Nagano, Japan) equipped with a triple-pass filter (DAPI/
Green/Orange; Vysis). The assessment and interpretation of
FISH results were made according to guidelines defined by the
SIOP Europe Neuroblastoma Pathology and Biology and Bone
Marrow Group [26]. For each probe, more than 100 non
overlapping nuclei were enumerated per hybridization. Tumors
with more than 30% of nuclei showing DNA loss were defined as
tumor with chromosomal loss.
IDH1/2 sequence analysis
IDH1 and IDH2 genes were sequenced in 280 gliomas,
including 105 astrocytic, 104 oligoastrocytic, and 71 oligoden-
droglial tumors.
Genomic DNA was isolated from snap-frozen tissue using the
QIAmp DNA mini-kit, as described by the manufacturer (Qiagen).
A fragment of 254 bp length spanning the catalytic domain of
IDH1 including codon 132 was amplified using the sense primer
IDH1 F: 59-ACCAAATGGCACCATACG-39 and the antisense
primer IDH1 R: 59-TTCATACCTTGCTTAATGGGG-39.A
fragment of 293 bp length spanning the catalytic domain of IDH2
including codon 172 was amplified using the sense primer IDH2
F: 59-GCTGCAGTGGGACCACTATT-39 and the antisense
primer IDH2 R: 59-TGTGGCCTTGTACTGCAGAG 9. PCR
using standard buffer conditions, 30 ng of DNA and GoTaq DNA
Polymerase (TaKaRa, Japan) employed 35 cycles with denaturing
at 95uC for 30 s, annealing at 54uC for 45 s and extension at 72uC
for 50 s in a total volume of 25 mL. The PCR amplification
product was sent to Beijing Tianyi Huiyuan Bioscience and
Technology Incorporation for sequencing.
Tumor location
Tumor location was considered to be the lobe or region of the
brain, in which the bulk of the tumor resided. They were specified
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10 (ICD-10) as previously described by Larjavaara [18]. Besides,
we added additional two locations: gliomas in the insular lobe were
assigned according to the classification of tumors of limbic and
pralimbic systems by Yasargil [27] and gliomas in thalamus, basal
ganglia or ventricle were defined as deeply located tumors. These
assignments were based on the evaluation of the MR images,
including T1-weighted axial, coronary, and sagital images before
and after Gadolinium enhancement and T2-weighted axial
images.
Statistical analysis
Chi-square (x
2) test was used for the comparison of differences
among regional constituents of pathological subsets, regional
percentages of tumor subsets and regional incidences of 1p/19q
co-deletion and IDH1/2 mutation. SPSS 13.0 (SPSS for
Windows, version 13.0 [SPSS Inc., Chicago, Illinois, USA]) was
used for statistical analysis. Probability value was obtained from 2-
sided tests, with a statistical significance of P,0.05.
Results
Regional constituents of tumor pathologies (Figure 1)
Pathological constituents of gliomas of the frontal origin (A
15.1%, AA 7.3%, G 12.8%, O 18.8%, AO 9.2%, OA 22.5%, and
AOA 14.2%) was significantly different from that of non-frontal
origin (A 24.2%, AA 9.4%, G 19.4%, O 12.6%, AO 5.5%, OA
16.1% and AOA 12.9%) (P=0.007). The percentage of
astrocytoma in gliomas of the frontal origin (15.1%) was
significantly lower than that of non-frontal origin (24.2%)
(P=0.011). The percentage of glioblastoma in gliomas of the
frontal origin (12.8%) was significantly lower than that of non-
frontal origin (19.4%) (P=0.048). The percentage of oligoden-
droglioma in gliomas of the frontal origin (18.8%) was significantly
higher than that of non-frontal origin (12.6%) (P=0.049). The
percentage of oligoastrocytoma in gliomas of the frontal origin
(22.5%) showed a trend to be higher than that of non-frontal
origin (16.1%), but the difference did not reach statistical
significance (P=0.066).
Pathological constituents of gliomas of the temporal origin (A
21.7%, AA 11.3%, G 31.3%, O 7.8%, AO 6.1%, OA 7.0%, and
AOA 14.8%) was significantly different from that of non-temporal
origin (A 20.1%, AA 7.7%, G 12.6%, O 17.2%, AO 7.3%, OA
22.0% and AOA 13.1%) (P,0.001). The percentage of glioblas-
toma in gliomas of temporal origin (31.3%) was significantly
higher than that of non-temporal origin (12.6%) (P,0.001). The
percentage of oligodendroglioma in gliomas of the temporal origin
(7.8%) was significantly lower than that of non-temporal origin
(17.2%) (P=0.013). The percentage of oligoastrocytoma in
gliomas of the temporal origin (7.0%) was significantly lower than
that of non-temporal origin (22.0%) (P,0.001).
Pathological constituents of gliomas of the insular origin (A
34.3%, AA 1.4%, G 5.7%, O 15.7%, AO 2.9%, OA 32.9% and
AOA 7.1%) was significantly different from that of non-insular
origin (A 18.3%, AA 9.6%, G 18.3%, O 15.1%, AO 7.6%, OA
16.6% and AOA 14.4%) (P,0.001). The percentage of astrocy-
toma in gliomas of the insular origin (34.3%) was significantly
higher than that of non-insular origin (18.3%) (P=0.002). The
percentage of oligoastrocytoma in gliomas of the insular origin
(32.9%) was significantly higher than that of non-insular origin
(16.6%) (P=0.001). The percentage of anaplastic astrocytoma in
gliomas of the insular origin (1.4%) was significantly lower than
that of non-insular origin (9.6%) (P=0.022). The percentage of
glioblastoma (5.7%) was significantly lower than that of non-
insular origin (18.3%) (P=0.008). The percentage of anaplastic
oligoastrocytoma (7.1%) showed a trend to be lower than that of
non-insular origin (14.4%), but the difference did not reach
statistical significance (P=0.097).
The percentage of astrocytoma in gliomas of the occipital origin
(41.2%) showed a trend to be higher than that of non-occipital
origin (19.8%), but the difference did not reach significance
(P=0.065). The percentage of astrocytoma in deeply located
gliomas (33.3%) showed a trend to be higher than that of other
origin (19.8%), but the difference did not reach significance either
(P=0.089).
Gliomas of frontal, temporal and insular origins harbored
significantly different pathological constituents (P,0.001), whereas
the pathological constituents of gliomas in the left, right and
bilateral sides were not significantly different (P=0.589).
Figure 1. Gliomas of frontal, temporal and insular origin had
significantly different pathological constituents of tumor
subsets. The percentage of astrocytoma in gliomas of the frontal
origin (15.1%) was significantly lower than that of non-frontal origin
(24.2%) (P=0.011). The percentage of glioblastoma in gliomas of the
frontal origin (12.8%) was significantly lower than that of non-frontal
origin (19.4%) (P=0.048). The percentage of oligodendroglioma in
gliomas of the frontal origin (18.8%) was significantly higher than that
of non-frontal origin (12.6%) (P=0.049). The percentage of glioblastoma
in gliomas of the temporal origin (31.3%) was significantly higher than
that of non-temporal origin (12.6%) (P,0.001). The percentage of
oligodendroglioma in gliomas of the temporal origin (7.8%) was
significantly lower than that of non-temporal origin (17.2%) (P=0.013).
The percentage of oligoastrocytoma in gliomas of the temporal origin
(7.0%) was significantly lower than that of non-temporal origin (22.0%)
(P,0.001). The percentage of astrocytoma in gliomas of the insular
origin (34.3%) was significantly higher than that of non-insular origin
(18.3%) (P=0.002). The percentage of oligoastrocytoma in gliomas of
insular origin (32.9%) was significantly higher than that of non-insular
origin (16.6%) (P=0.001). The percentage of anaplastic astrocytoma in
gliomas of the insular origin (1.4%) was significantly lower than that of
non-insular origin (9.6%) (P=0.022). The percentage of glioblastoma
(5.7%) was significantly lower than that of non-insular origin (18.3%)
(P=0.008). A=astrocytoma; AA=anaplastic astrocytoma; G=glioblas-
toma; O=oligodendroglioma; AO=anaplastic oligodendroglioma;
OA=oligoastrocytoma; AOA=anaplastic oligoastrocytoma.
doi:10.1371/journal.pone.0032764.g001
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different regions and sides of the brain, irrespective of
pathology (Table 1 and Figure 2 and 3)
In 339 gliomas, the mean global incidence of 1p/19q co-
deletion was 36.6%. Irrespective of pathology, the incidence of
1p/19q co-deletion in gliomas of the frontal origin (50.4%) was
significantly higher than that of non-frontal origin (27.0%)
(P,0.001). The incidence of 1p/19q co-deletion in gliomas of
the temporal origin (23.9%) was significantly lower than that of
non-temporal origin (39.9%) (P=0.013). The incidence of 1p/19q
co-deletion in deeply located gliomas (13.3%) showed a trend to be
lower than that of non-deeply located gliomas (37.7%), but the
difference did not reach statistical significance (P=0.056).
Furthermore, the incidences of 1p/19q co-deletion in the left,
right and bilateral sides of the brain (41.3%, 31.7% and 39.1%,
respectively) did not show a significant difference (P=0.200).
In 280 gliomas, the mean global incidence of IDH1/2 mutation
was 58.6%. Irrespective of pathology, the incidence of IDH1/2
mutation in gliomas of the frontal origin (73.5%) was significantly
higher than that of non-frontal origin (48.5%) (P,0.001). The
incidence of IDH1/2 mutation in gliomas of the temporal origin
(41.7%) was significantly lower than that of non-temporal origin
(63.2%) (P=0.003). The incidence of IDH1/2 mutation in gliomas
of parietal origin (43.3%) showed a trend to be lower than that of
non-parietal origin (60.4%) (P=0.073). Furthermore, the incidence
of IDH1/2 mutation in deeply located gliomas (35.7%) showed a
trend to be lower than that of non-deeply located gliomas (59.8%)
(P=0.075). The incidences of IDH1/2 mutation in the left, right
and bilateral sides of the brain (59.1%, 57.8% and 61.1%,
respectively) did not show a significant difference (P=0.954).
Regional incidences of co-deletion of chromosome 1p/
19q and IDH1/2 mutation in subgroups (Table 1 and
Figure 2 and 3)
In 111 oligoastrocytic tumors (Grade II and III), the mean
global incidence of 1p/19q co-deletion was 42.3%. The incidences
in Grade II and Grade III (43.1% and 41.3%, respectively) were
not significantly different (P=0.852). The incidence of 1p/19q co-
deletion in oligoastrocytic tumors of the frontal origin (58.0%) was
significantly higher than that of non-frontal origin (29.5%)
(P=0.003). The incidence of 1p/19q co-deletion in oligoastrocytic
tumors of the temporal origin (18.8%) was significantly lower than
that of non-temporal origin (46.3%) (P=0.039). For oligoastrocytic
tumors, however, the incidences of 1p/19q co-deletion between
different sides of the brain (47.1%, 36.5% and 50.0%, respectively)
were not significantly different.
In 104 oligoastrocytic tumors (Grade II and III), the mean
global incidence of IDH1/2 mutation was 54.8%. The incidences
in Grade II and Grade III were not significantly different
(P=0.340). The incidence of IDH1/2 mutation in oligoastrocytic
tumors of the frontal origin (70.0%) was significantly higher than
that of non-frontal origin (45.3%) (P=0.014). The incidence of
IDH1/2 mutation in oligoastrocytic tumors of the temporal origin
(30.4%) was significantly lower than that of non-temporal origin
(61.7%) (P=0.008). The incidence of IDH1/2 mutation in
oligoastrocytic tumors of the insular origin (81.3%) was signif-
icantly higher than that of non-insular origin (50.0%) (P=0.021).
For oligoastrocytic tumors, however, the incidences of IDH1/2
mutation between different sides of the brain (57.4%, 50.0% and
100.0%, respectively) were not significantly different.
In 78 oligodendroglial tumors (Grade II and III), the mean
global incidence of 1p/19q co-deletion was 74.4%. The incidences
in Grade II and Grade III (78.6% and 63.6%, respectively) were
not significantly different (P=0.174). The incidence of 1p/19q co-
deletion in oligodendroglial tumors of the frontal origin (84.6%)
was significantly higher than that of non-frontal origin (64.1%)
(P=0.038). The incidence of 1p/19q co-deletion in oligodendrog-
lial tumors of the temporal origin (50.0%) showed a trend to be
lower than that of non-temporal origin (78.8%), but the difference
did not reach significance (P=0.082). For oligodendroglial tumors,
however, the incidences of 1p/19q co-deletion between different
sides of the brain (76.9%, 68.6% and 100.0%, respectively) were
not significantly different.
Figure 2. Gliomas of frontal and temporal origin had signifi-
cantly different incidences of 1p/19q co-deletion irrespective
and in respective of tumor pathology. The regional incidences of
1p/19q co-deletion in all gliomas of the region irrespective of pathology
were labeled with ‘‘All’’. The regional incidences of 1p/19q co-deletion
in respective of pathology were labeled with ‘‘A+AA+G, O+AO and
OA+AOA’’ respectively. *The incidence of 1p/19q co-deletion in this
region is significantly higher or lower than that in other regions
(p,0.05, chi-square test).
doi:10.1371/journal.pone.0032764.g002
Figure 3. Gliomas of frontal and temporal origin had signifi-
cantly different incidences of IDH1/2 mutation irrespective and
in respective of tumor pathology. The regional incidences of IDH1/
2 mutation in all gliomas of the region irrespective of pathology were
labeled with ‘‘All’’. The regional incidences of IDH1/2 mutation in
respective of pathology were labeled with ‘‘A+AA, O+AO and OA+AOA’’
respectively. *The incidence of IDH1/2 mutation in this region is
significantly higher or lower than that in other regions (p,0.05, chi-
square test).
doi:10.1371/journal.pone.0032764.g003
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global incidence of IDH1/2 mutation was 81.7%. The incidences
in Grade II and Grade III (81.8% and 76.5%, respectively) were
not significantly different (P=0.892). The incidence of IDH1/2
mutation in oligodendroglial tumors of the frontal origin (92.7%)
was significantly higher than that of non-frontal origin (66.7%)
(P=0.005). The incidence of IDH1/2 mutation in oligodendrog-
lial tumors of the temporal origin (40.0%) was significantly lower
than that of non-temporal origin (88.5%) (P=0.001). For
oligodendroglial tumors, however, the incidences of IDH1/2
mutation between different sides of the brain (84.8%, 75.8% and
100.0%, respectively) were not significantly different.
In 150 astrocytic tumors (Grade II, III and IV), the mean global
incidence of 1p/19q co-deletion was 12.7%. The incidences in
Grade II, III and IV (12.1%, 12.9% and 13.2%, respectively) were
not significantly different (P=0.983). Astrocytic tumors did not
show different incidences of 1p/19q co-deletion with respect to
tumor location. For astrocytic tumors, the incidences of 1p/19q
co-deletion between different sides of the brain (15.4%, 10.8% and
9.1%, respectively) were not significantly different either.
In 105 astrocytic tumors (Grade II and III), the mean global
incidence of IDH1/2 mutation was 46.7%. The incidences in
Grade II and III (51.4% and 36.6%, respectively) were not
significantly different (P=0.129). The incidence of IDH1/2
mutation in astrocytic tumors of parietal origin (0.0%) was
significantly lower than that of non-parietal origin (51.0%)
(P=0.003). For astrocytic tumors, the incidences of IDH1/2
mutation between different sides of the brain (42.6%, 54.2% and
30.0%, respectively) were not significantly different.
Discussion
In the present study, we reviewed a series of 528 cases of gliomas
retrospectively and compared regional constituents of pathological
subsets, regional incidences of 1p/19q co-deletion and IDH1/2
mutation. This study provided a detailed incidence map of glioma
subsets (relative), 1p/19q co-deletion and IDH1/2 mutation cross
the brain in Chinese patients. The results revealed that gliomas of
frontal, temporal and insular origins had significantly different
pathological constituents of tumor subsets (P,0.001). We also
showed that gliomas of the frontal lobe had significantly higher
incidence of 1p/19q co-deletion (50.4%) and IDH1/2 mutation
(73.5%) than those of non-frontal origin (27.0% and 48.5%,
respectively), while gliomas of the temporal origin have signif-
icantly lower incidence of 1p/19q co-deletion (23.9%) and IDH1/
2 mutation (41.7%) than those of non-temporal origin (39.9% and
63.2%, respectively). Subgroup analysis also confirmed these
findings in oligoastrocytic and oligodendroglial tumors. These
findings revealed preferential distribution of pathological subsets,
1p/19q co-deletion, and IDH1/2 mutation and implied the
distinctiveness among different brain lobes.
The most important finding of our study is the preferential
distribution of IDH1/2 mutation in the frontal lobe (73.5%)
instead of the temporal lobe (41.7%). This finding was also
confirmed in subgroup analysis. Although Lai reported a striking
predominance of frontal lobe involvement of primary GBM with
IDH1 mutation [25], we provided a more detailed incidence map
of IDH1/2 mutation in diffuse gliomas (WHO grade II and III)
cross the brain and revealed the preferential distribution of IDH1/
2 mutation. The distribution of IDH1/2 mutation resembles that
of 1p/19q co-deletion and provided another evidence for the
distinctiveness of gliomas from different brain lobes.
In our study, we found that gliomas of different lobes had
different constituents of pathological subsets, especially in frontal,
temporal, and insular lobes. For example, gliomas of frontal origin
were more likely to be oligodendroglioma and less likely to be
astrocytoma and glioblastoma than those of non-frontal origin.
Gliomas of the temporal origin were more likely to be glioblastoma
and less likely to be oligodendroglioma and oligoastrocytoma than
those of non-temporal origin. Gliomas of insular origin were more
likely to be astrocytoma and oligoastrocytoma and less likely to be
glioblastoma and anaplastic astrocytoma than those of non-insular
origin. For the first time, we found that gliomas of the temporal
origin were more likely to be glioblastomas. Furthermore, we
Table 1. Regional frequencies of 1p/19q co-deletion and IDH1/2 mutation in glioma subsets.
Frequency in different lobes Frequency in different sides
Pathology
Molecular
alteration Frequency Frontal Temporal Insular Parietal Occipital
Fronto-
parietal
Deeply
located Left Right Bilateral
O+AO 1p/19q co-
deletion
58/78 33/39 6/12 9/10 6/10 - 2/4 2/3 30/39 24/35 4/4
O+AO IDH1/2
mutation
58/71 38/41 4/10 6/8 7/8 - 3/3 0/1 28/33 25/33 5/5
OA+AOA 1p/19q co-
deletion
47/111 29/50 3/16 9/20 3/13 1/1 2/8 0/3 24/51 19/52 4/8
OA+AOA IDH1/2
mutation
57/104 28/40 7/23 13/16 6/13 0/2 2/7 1/3 27/47 27/54 3/3
A+AA+G 1p/19q co-
deletion
19/150 8/50 8/43 1/19 1/10 0/8 1/11 0/9 10/65 8/74 1/11
A+AA IDH1/2
mutation
49/105 17/32 14/27 8/17 0/9 5/6 1/4 4/10 20/47 26/48 3/10
Total 1p/19q co-
deletion
124/339 70/139 17/71 19/49 10/33 1/9 5/23 2/15 64/155 51/161 9/23
IDH1/2
mutation
164/280 83/113 25/60 27/41 13/30 5/8 6/14 5/14 75/127 78/135 11/18
A: astrocytomas; AA: anaplastic astrocytoma; G: glioblastoma; O: oligodendrogliomas; AO: anaplastic oligodedroglioma; OA: oligoastrocytomas; AOA: anaplastic
oligoastrocytoma; IDH: isocitrate dehydrogenase gene; (-): no data available. Numbers of cases with alterations are given in respect to cases examined.
doi:10.1371/journal.pone.0032764.t001
1p/19q Co-Deletion and IDH1/2 Mutation in Gliomas
PLoS ONE | www.plosone.org 5 March 2012 | Volume 7 | Issue 3 | e32764found that low-grade gliomas were preferentially located in the
insula, as was suggested by Duffau [19]. These results implied that
astrocytic precursor cells were preferentially located in the
temporal lobe or that the regional microenvironment in the
temporal lobe facilitated the genesis of astrocytic tumors. It also
implied that the oligodendroglial precursor cells were preferen-
tially located in the frontal lobe or that the frontal microenviron-
ment facilitated the genesis of oligodendroglial tumors. The
preferential distribution of pathological subsets implies correlation
between glioma subsets and locations, which will facilitate further
investigation of glioma initiation.
According to our results, gliomas of the frontal origin were more
likely to harbor prognostic 1p/19q co-deletion than those of non-
frontal origin (P,0.001), while gliomas of the temporal origin were
less likely to harbor this genetic signature than those of non-
temporal origin. In our study, subgroup analysis confirmed the
finding that the incidence of 1p/19q co-deletion was higher in the
frontal lobe and lower in the temporal lobe in both oligodendrog-
lial and oligoastrocytic tumors. Compared with previous reports,
our report provided a more detailed incidence map of 1p/19q co-
deletion across the brain in a much larger sample size (Table 2).
Zlatescu et al. found that tumors had allelic loss of chromosomes
1p and 19q in anaplastic oligoastrocytoma occurred most
frequently in the frontal lobes (53%) and having a tendency for
widespread growth across the midline [20]. In Mueller’s report,
the frequency of 1p/19q co-deletion in the temporal lobe (23.1%)
was less than that in non-temporal lobes (81.7%) in oligoden-
droglial tumors and the frequency in the temporal lobe (33.3%)
was less than that in non-temporal lobes (71,4%) in oligoastrocytic
tumors [21]. Besides, Huang et al. found that oligodendrogliomas
located in the non-temporal lobes were significantly more likely to
harbor 1p/19q co-deletion than tumors arising in the insular,
temporal lobe, and temporal with another lobe [22].
Our study demonstrated a high incidence of 1p/19q co-deletion
in insular oligoastrocytic and oligodendroglial tumors (45.0% and
90.0% respectively). The incidence of 1p/19q co-deletion in
gliomas of the insular origin was not significantly different from
that of non-insular origin, as far as astrocytic, oligoastrocytic or
oligodendroglial tumors were concerned, respectively. It was
disputable that gliomas in the insular lobe had a lower incidence of
1p/19q co-deletion. Goze et al. [23] studied co-deletion of 1p/19q
in a series of 12 Grade II gliomas, including 11 oligodendrogli-
omas and 1 oligoastrocytoma, in which they found no complete
deletion of 1p/19q in them. However, Wu et al. [24] analyzed a
series of insular oligodendroglial tumors (n=14) and found that
the frequencies of co-deletion of 1p/19q were 50% in oligoden-
drogliomas (Grade II and III, n=8) and 67% in oligoastrocytomas
(Grade II and III, n=6) [24]. Our study with the largest series of
patients demonstrated high frequencies of 1p/19q co-deletion in
oligodendroglial (90.0%, n=10) and oligoastrocytic tumors
(45.0%, n=20) of the insular origin. Thanks to the preferential
distribution of low-grade gliomas in the insular lobe with a
common incidence of 1p/19q co-deletion, favorable outcomes can
be expected as reported by Sanai et al. [28]. However,
complicated insular anatomy challenges surgical strategies of
neurosurgeons [29].
However, selection bias in the present study might exist in this
series of glioma patients surgically treated, as the outpatients were
not included in the analysis. All the patients were selected for
surgery according to the indication and the self-decision of
patients, so the composition of tumor types and grades presented
here may not be consistent with general frequencies of glioma
subsets, which is a weakness of our study.
Besides, problems with assigning tumors to specific brain
regions exist in a few cases. In these cases, tumor invading more
than one lobe was assigned to the lobe, where the bulk resided, as
was described in the material and methods. In 34 tumors involving
both frontal and parietal lobes, the ratio of volume was
approximately 1:1, so they were assigned to the frontoparietal
region. In spite of these weaknesses, our results and conclusions
about constituents of tumor subsets, incidences of 1p/19q co-
deletion and IDH 1/2 mutation are convincing and reliable.
In conclusion, by comparing regional constituents of patholog-
ical subsets, incidences of 1p/19q co-deletion and IDH1/2
mutation in Chinese patients with gliomas, preferential distribu-
tion of tumor subsets, 1p/19q co-deletion and IDH1/2 mutation
was confirmed in certain brain regions, implying their distinctive-
ness in tumor genesis and predictive value for prognosis in Chinese
patient populations.
Table 2. Regional molecular heterogeneity about chromosome 1p/19q and IDH1/2 in gliomas reported in English literature.
Authors Sample size Findings
Zlatescu et al [20] N=64 Anaplastic oligoastrocytomas located in the frontal, parietal, and occipital lobes (65.6%) were significantly more likely to
harbor allelic loss of chromosome arms 1p and 19q than histologically indistinguishable tumors arising in the temporal
lobe, insula, and diencephalon (34.4%) (P,0.001).
Mueller et al [21] N=203 The frequency of 1p/19q co-deletion in the temporal lobe (23.1%) were less than that in non-temporal lobes (81.7%) in
oligodendroglial tumors (P,0.001) and the frequency in the temporal lobe (33.3%) were less than that in non-temporal
lobes (71.4%) in oligoastrocytic tumors (P=0.004).
Laigle-Donadey et al [30] N=158 Oligodendrogliomas with chromosome 1p deletion was located preferentially in the frontal lobes as compared with the
temporal, parietal, and occipital tumors.
Huang et al [22] N=105 The combination of LOH 1p and LOH 19q occurred in 26 of 44 (59.1%) non-temporal oligodendroglial tumors, and only 5
of 26 (19.2%) oligodendroglial tumors involving the insular, temporal, and temporal with another lobe (P=0.001). The
combination of LOH 1p and LOH 19q occurred in 14 of 26 (53.8%) non-temporal oligoastrocytic tumors, and only 4 of 16
(25%) oligoastrocytic tumors involving the insular, temporal, and temporal with another lobe (P=0.067).
Present report N=339 Gliomas of frontal origin have significantly higher incidence of 1p/19q co-deletion (50.4%) and IDH1/2 mutation (73.5%)
than those of non-frontal origin (27.0% and 48.5%, respectively) (P,0.001), while gliomas of temporal origin have
significantly lower incidence of 1p/19q co-deletion (23.9%) and IDH1/2 mutation (41.7%) than those of non-temporal
origin (39.9% and 63.2%, respectively) (P=0.013 and P=0.003, respectively). Subgroup analysis confirmed these findings
in oligoastrocytic and oligodendroglial tumors (WHO II and III), respectively. Although the difference of 1p/19q co-
deletion in temporal oligodendroglial tumors was marginally significant (P=0.082).
doi:10.1371/journal.pone.0032764.t002
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